ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1775

The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline

Jack Mordeson1, Nozima Aripova1, Michael Duryee1, James O'Dell1, Bryant England1, Daniel Anderson1, Ted R Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, citrullination, Fibroblasts, Synovial, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90% specific for the diagnosis of RA. Our laboratory has shown co-localization of MAA with citrullinated proteins in RA synovial fluid, elevated anti-MAA antibodies in RA patients, and pro-inflammatory and pro-fibrotic responses to MAA-modified antigens by macrophages in vitro. In addition, macrophages demonstrate increased expression of peptidyl arginine deiminase-2 (PAD2), an isozyme of PAD, in response to these MAA-adducted and citrullinated proteins. PAD catalyzes protein citrullination and may mediate the immunogenic transformation of synovial proteins and subsequent auto-antibody formation in RA. Here, we determine whether inhibition of PAD effects inflammatory and fibrotic markers in macrophages and RA human fibroblast-like synoviocytes (HFLS-RA) in response to stimulation with MAA and citrulline (CIT)-modified fibrinogen (FIB).

Methods: U-937 monocyte cell line was differentiated into activated macrophages by exposure to LPS, and subsequently stimulated with; unmodified FIB, FIB-CIT, or FIB-MAA-CIT in the presence (treatment group) and absence (control group) of BB-CLA (a general PAD inhibitor; PADi) for 48 hours. Supernatants collected from the media were assessed by ELISA for the pro-inflammatory cytokines; interleukin-1b (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1). HFLS from RA patients were stimulated with treatment and control supernatants from the antigen-stimulated macrophage cultures and assessed via immunofluorescent staining for the fibrotic markers vimentin and type II collagen.

Results: As previously reported, the modification of FIB with CIT and or MAA-CIT statistically increases the concentrations of the pro-inflammatory cytokines measured (Figure 1 A-D, Control). The effect of PAD inhibition on the inflammatory cytokine levels was a decrease in the secretion by stimulated macrophages of these cytokines (Figure 1 A-D, +BB-CLA) back to almost baseline levels. Examination of the HFLS cells stimulated with supernatants from macrophages activated with FIB-CIT or FIB-MAA-CIT showed an increase in both vimentin and Type II Collagen production that was significantly elevated when compared to FIB supernatant stimulation (Figure 2 A-C).

Conclusion: This study provides insight into the degree to which inflammatory and fibrotic responses from macrophages and HFLS to CIT and MAA-CIT modified fibrinogen may be PAD-mediated. Therefore, these observations strongly suggest that CIT and MAA-CIT modification of proteins play a role in the inflammatory and fibrotic responses observed in cells associated with RA development and/or progression. Additionally, they suggest that PAD inhibition is an obvious target for therapeutic intervention.

Supporting image 1

Figure 1. Inflammatory cytokines from stimulated U-937 cells. U-937 cells were stimulated with native and modified fibrinogen for 48 hours in the presence and absence of BB-CLA. IL_1β (A), IL-6 (B), IL-8 (C), and MCP_1 (D) levels were measured via ELISA. ****p<0.001.

Supporting image 2

Figure 2. Fibrotic markers from stimulated HFLS-RA cells. U-937 supernatants were utilized for stimulation of HFLS-RA cells. Images were recorded following immunofluorescent staining with anti-vimentin and anti-type II collagen antibodies. ****p<0.001, #p<0.05.


Disclosures: J. Mordeson: None; N. Aripova: None; M. Duryee: None; J. O'Dell: None; B. England: Boehringer-Ingelheim, 2, 5; D. Anderson: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9; G. Thiele: None.

To cite this abstract in AMA style:

Mordeson J, Aripova N, Duryee M, O'Dell J, England B, Anderson D, Mikuls T, Thiele G. The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-peptidyl-arginine-deiminase-inhibitor-bb-cla-decreases-the-inflammatory-and-fibrotic-responses-in-macrophages-and-rheumatoid-arthritis-synovial-fibroblasts-exposed-to-fibrinogen-modified-with-malo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-peptidyl-arginine-deiminase-inhibitor-bb-cla-decreases-the-inflammatory-and-fibrotic-responses-in-macrophages-and-rheumatoid-arthritis-synovial-fibroblasts-exposed-to-fibrinogen-modified-with-malo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology